A systematic review published in Cureus examines the efficacy and safety of both topical and systemic therapies for atopic dermatitis (chronic eczema characterised by impaired skin-barrier function and itch) in patients with skin of colour. The review aggregates published evidence on treatments spanning corticosteroids, calcineurin inhibitors and systemic agents, a scope few syntheses in this field attempt.

The clinical problem is well documented. Atopic dermatitis presents differently across phototypes: erythema (redness) is harder to visualise on darker skin, where violaceous, hyperpigmented or lichenified changes may dominate. That visual mismatch affects trial enrolment, endpoint scoring and, ultimately, the generalisability of registrational data, most of which was generated in predominantly light-skinned cohorts.

What does the review cover?

The authors systematically appraised studies of:

• Topical therapies, including anti-inflammatory agents applied to lesional skin
• Systemic therapies, including immunomodulatory agents for moderate-to-severe disease
• Safety outcomes reported specifically for patients with skin of colour

By pairing efficacy with safety data, the review addresses a gap that single-agent trials rarely close. Whether the underlying studies used validated severity instruments adjusted for pigmentation, however, is a question the review itself must answer; scoring tools such as EASI (Eczema Area and Severity Index, a 0–72 composite of lesion extent and severity) were largely validated on lighter phototypes.

Why the cohort matters

Patients with skin of colour frequently carry a disproportionate burden of atopic dermatitis, with higher reported prevalence in some populations and a greater tendency toward post-inflammatory pigmentary change. A treatment that clears eczema activity but leaves persistent dyspigmentation may satisfy a trial endpoint while failing the patient. Reviews that stratify both efficacy and adverse events by phototype are therefore a structural necessity rather than an academic refinement.

The caveat is familiar. A systematic review is only as strong as the primary literature it retrieves, and trials reporting outcomes by skin type remain scarce. Conclusions in this paper should be read as a map of the evidence, not as new effect sizes.

What is still not said

Neither the title nor the accompanying material specifies the number of studies pooled, the total patient count, or the review's registration status. Without those figures, clinicians cannot yet judge the weight of the synthesis. Readers should verify whether the authors graded certainty of evidence, reported subgroup analyses by Fitzpatrick phototype (a I–VI scale of skin's response to ultraviolet light), and disclosed funding before translating any finding into practice.

The review's appearance in Cureus, a peer-reviewed open-access journal, places it within the cited literature, but open-access publication alone does not substitute for meta-analytic rigour.

The practical takeaway

For dermatologists managing atopic dermatitis in skin of colour, this synthesis offers a consolidated reference on which topical and systemic options carry documented efficacy and safety signals in this population. It does not, on the available information, replace phototype-stratified trial data.

Future registrational trials that prespecify skin-of-colour subgroups, and validated severity scoring adjusted for pigmentation, will determine whether reviews like this one become outdated summaries — or remain the best available evidence for years to come.